H. Steven Moffic, MD, talks climate change and the lukewarm climate summit. He poses the question, who are you and how do you identify as a citizen of this planet? 

To see the last video in this series, watch 

What About Love and the Golden Rule, the Platinum Rule, and the Walrus Rule.

To see the latest in his column series, Psychiatry Views On The Daily News, see 

Psychedelics Providing Hope for Veterans and Others.

is an award-winning psychiatrist who has specialized in the cultural and ethical aspects of psychiatry. A prolific writer and speaker, he received the one-time designation of Hero of Public Psychiatry from the Assembly of the American Psychiatric Association in 2002. He is an advocate for mental health issues relate to climate instability, burnout, Islamophobia, and anti-Semitism for a better world. He serves on the Editorial Board of

Videos

What About Love of the Earth

 is an undergraduate studying neuroscience at Dartmouth College.

is a neuroscientist at the Global Brain Health Institute.

is an adjunct faculty member at UC Berkeley and Singularity University.

is a venture partner at Alsop Louie Partners.

a Senior Clinical Advisor for Cohen Veterans Bioscience’s Trauma Research Programs. She serves as Strategic Advisor co-leading CVB’s Suicide Strategy Initiative.

is a professor of Law and Health Sciences at the University of Surrey School of Law and adjunct assistant professor of Medicine at the David Geffen School of Medicine at UCLA.

 is venture capitalist, founder and managing partner at Newfund Capital.

professor of psychiatry at the University Paris Est Créteil, in charge of the psychiatric and addiction centre at the Henri Mondor University Hospitals, director of the DHU PePSY, and director of the laboratory of “Psychiatrie Translationelle” Inserm U955, France. She is also operational director of the FondaMental Foundation.

is the senior science and technology manager of the US Army Engineer Research and Development Center (ERDC) and an adjunct professor at Carnegie Mellon University. He is responsible for ERDC’s project portfolio in the areas of crises management and resilience. He has published widely on environmental and technology policy, and on risk and resilience analytics, including 25 books and more than 400 peer-reviewed papers and book chapters.

As brain health investing sees unprecedented growth and activity, how do we ensure a sustainable rate of progress going forward? An editorial in 

reported that “In 2019 alone, venture capital (VC) companies invested a record-breaking $637 million in more than 60 different mental health-oriented companies.”

 This has accelerated further in 2020 and 2021.

 The whole VC field is booming, and beyond just mental health care, investment in the broader field of brain health science and technology is also on the rise.

There is a good reason for this: Brain health technologies are essential clinical tools for addressing the global brain health pandemic and its multiple social and technological changes.

 These technologies—spanning omics, digital therapeutics, artificial intelligence, and devices—aim to improve access, screening, prevention, diagnosis, and treatment. There is an increasing convergence of these types of solutions as clinicians, health systems, and payors attempt to simplify clinical workflows and minimize fragmentation of new products and services (

With investment in brain health growing so quickly, it is easy to be optimistic about the current and future state of the field. Recent societal trends reinforce the ostensibly rosy picture. The COVID-19 pandemic accelerated the destigmatization of mental illnesses and highlighted the importance of brain health to the public.

 Similarly, the pandemic has unveiled as never before intrinsic connections between mental and brain health, economy, innovation, and wellbeing.

 It is crucial, though, that we do not take progress for granted and rest on our laurels. It is also critical that we take a responsible approach to this field, which is very vulnerable to hope (due to the dire suffering and intense want for relief) and hype (due to major business opportunities).

Indeed, the stakes are too high. Given the multi-trillion-dollar costs of mental health disorders, the poor standard of routine care, and the projected rises in prevalence and economic burden of mental health disorders in the coming decades, 

 The show must go on! In order to protect and reinforce the vibrant brain health ecosystem, we must anticipate risks of market failure and work to proactively mitigate them. We wrote about this 

; however, this article is a much more extensive thesis and set of recommendations.

) is a graphical depiction of a common pattern that arises with each new technology or other innovation.

 It represents the maturity, adoption, and social application of specific technologies (

). We believe the Hype Cycle is relevant to the frontier brain health technology field and can provide a cautionary tale for the field.

Risks for the Frontier Brain Health Technology Field

We are seeing signs of “Peak of Inflated Expectations” in this field. There are regular news articles touting the rising rates of VC investment, which have helped create a record number of brain health “unicorn” companies (companies valued over $1 billion).

 Concerns have been raised over the emergence of public disclosure of speculative valuations and seemingly inflated valuations (for instance, the digital therapeutics company Pear Therapeutics achieved a valuation of $1.6 billion with less than $4 million in revenue).

 Many commercially successful technologies have major consumer demand, but are not yet integrated into clinical workflows. There is also a common disconnect between commercially successful apps vs those that are validated and more likely to be accepted in clinical practice guidelines. Some have deemed the digital mental health technology field the “lawless wild west,” citing concerns around false claims and poor data privacy management practices.

 Digital phenotyping has failed to make it into clinical workflows.

Further, there are significant safety concerns from post-marketing safety data of a popular new antidepressant, esketamine.

 Such post-marketing data is often not taken into account in the initial go-to-market excitement. Of course, this data is in and of itself a cautionary tale for the psychedelics field, which has received huge investor interest and public interest.

 Psychedelics in psychiatry to date have no post-marketing data, and no study to date is powered to detect conversion to psychosis. Nonhallucinogenic forms of these molecules may be helpful.

 Taken together, these issues create significant concern for this field’s sustainability.

There is thus a risk that the field will slip into the “Trough of Disillusionment.” This will be disappointing, given that every company failure may represent potentially valuable products and services that will not help patients. Moreover, novel intellectual property will be lost. Much of this downward slide will be driven by conventional VC models that are suboptimal for the brain health technology field. Conventional or general VC models rely on financial executives with minimal to no domain experience. The 2/20 model values financial returns within a set timeframe and disincentivizes significant operational input from general partners (GPs).

 Additionally, strategies prevalent in technology startups may not always transfer well to health care startups (eg, “fake it ‘til you make it,” “move fast and break things,” and Theranos). Problems we observe with conventional VC models are outlined in 

How Conventional Venture Capital May Risk Sliding the Field Into the “Trough of Disillusionment”

A Brain Health Technology Market Sustainability Grand Strategy

We suggest a grand strategy that could enable the field to bypass the “Trough of Disillusionment” and progress directly to the “Plateau of Productivity.” VC remains a critical component, but we believe it is imperative to consider additional investment, operational, and governance approaches. We outline these approaches to optimize the field’s sustainability in 

Elements of a Brain Health Technology Market Sustainability Grand Strategy

To optimize the integrity and legitimacy of brain health technology investing, it is key to develop standards and best practices with major international stakeholders. Examples may include the World Health Organization, the United Nations, and the Organisation for Economic Co-Operation and Development (OECD). Engagement with these groups will support sustained engagement with sovereign wealth funds, pension funds, mutual funds, and other large multinational corporations. Moreover, to ensure a global impact, global stakeholders must face the challenges to assure brain health development in low- and middle-income countries (LMICs), where multiple structural conditions may block progress and sustainability. For example, the October 2021 WHO Mental Health Atlas outlined a global lack of progress in leadership, governance, and financing.

“None of the targets for effective leadership and governance for mental health, provision of mental health services in community-based settings, mental health promotion and prevention, and strengthening of information systems were close to being achieved.

The new UN Health Innovation Exchange is a step in the right direction aiming to connect funders, investors, and innovations. Other progress has recently been made. We 

 that the Sustainability Accounting Standards board included mental health and wellbeing in its proposed updated human capital standards.

 Also, a new ISO standard 45003 gives guidance on managing psychological health and safety risks within an occupational health and safety management system

; the Business Roundtable noted that the generation of a healthy environment is a key purpose of a corporation

; and the signatories of the Principles of Responsible Investing listed mental health as one of the top 4 social issue priorities in the future.

Further, the OECD’s New Approaches to Economic Challenges unit has established a Neuroscience-inspired Policy Initiative that seeks to reconceptualize and revitalize the economy and how it works in new ways, laying the groundwork to identify relevant metrics while building a transdisciplinary network of stakeholders. The initiative will rapidly refine and advance the concept of Brain Capital (a novel asset class grossing up brain health and brain skills) via a series of research projects, surveys, data collection, economic modeling, seminars, and clear policy analyses and recommendations.

Tracking Brain Health Technology Market Sustainability

Tracking metrics on this topic would be useful, given the risks outlined in this article. Metrics of company and market sustainability could offer investors greater ability to make scientifically and data-grounded investments and to ensure the field develops sustainably. However, developing representative metrics of company and market sustainability is challenging in a market where most investments flow into private companies. This precludes the use of typical financial metrics such as free cash flow and yearly revenue. While private companies will disclose data, it is likely that they will only release information that is self-serving and can generate interest from investors and the general public. Further, given the strength of the financial incentives of both limited partners and fund managers, it will be challenging to achieve a more sustainable approach. Financial incentives prioritize force feeding unicorns to maximize exit price and maximizing the share price of public companies. Most likely, metrics will need to be carefully developed by integrating data and judgment in a transparent way, possibly through the tools of multi-criteria decision analysis.

Tracking market sustainability is further challenged by the 

 inherent in a field largely reliant on highly technical advances.

 This enables companies to craft a reductionist and self-serving story of how their products function, a phenomenon exemplified by Theranos. Moreover, many life science companies themselves do not fully understand how their products work, which complicates efforts to overcome the information asymmetry rife in the brain health technology field.

Nonetheless, we believe there are available metrics that could help form an index of company and broader brain health market sustainability. These measures represent outputs that can help investors mitigate the risk of company and broader market failures. 

 outlines such elements that may be included in a proposed brain health market sustainability index.

Potential Components of a Brain Health Market Sustainability Index

 recently published a project mapping 50 emerging digital health technologies onto the Hype Cycle.

 We suggest that this type of project should be completed specifically in the brain health technology field, and it should involve surveys of diverse stakeholders from many countries. Then tracking where individuals believe brain health technology map onto the Hype Cycle in a yearly manner would be prudent to guide the field.

In the brain health technology field, there is considerable variability concerning where particular technologies and technology classes sit in the Hype Cycle. Therefore, further work is required to map specific examples onto the cycle. However, irrespective of where these examples stand, formalizing and employing the abovementioned sustainability strategy in the United States, where most investment is currently directed, could mitigate the risk of a broader brain health market failure.

 Of course, we believe our approach should also be deployed proactively outside the United States, especially as global investment begins to increase. We hope that it may even be possible to largely avoid the “Trough of Disillusionment” and reach the “Plateau of Productivity.” We believe our approach could sustain the brain health technology market for decades. Humanity deserves and needs it!

 is an undergraduate studying neuroscience at Dartmouth College. 

 is a director at the PRODEO Institute, an Atlantic Fellow in Brain Health Equity at the Global Brain Health Institute at the University of California, San Francisco, and a Thiel Fellow at Stanford University. 

 is cofounder of the PRODEO Institute and CEO of PRODEO. 

 is Alfred Deakin Professor of Psychiatry at Deakin University and director of IMPACT at Deakin University (Institute for Mental and Physical Health and Clinical Translation). 

 is the director of the Latin American Brain Health Institute, a senior researcher at the Universidad de San Andrés, and a Senior Atlantic Fellow at the GBHI at the UCSF and Trinity College Dublin. 

 is a venture capitalist and an adjunct faculty member at UC Berkeley and Singularity University. 

is a venture capitalist and an adjunct professor in engineering at Stanford University. 

 is a senior clinical advisor for Cohen Veterans Bioscience’s Trauma Research Programs who also serves as strategic advisor co-leading CVB’s Suicide Strategy Initiative. 

 is a corporate attorney, a professor of law at University of Surrey, and an adjunct professor with the UCLA David Geffen School of Medicine. 

 is venture capitalist, founder and managing partner at Newfund Capital. 

 is an undergraduate studying computer science at Stanford University. 

 is the CEO of Fondation FondaMental and professor of psychiatry at University Paris Est Créteil. 

 is a neurologist, neuroscientist, and technologist. He is an adjunct professor with the Department of Neurology at Johns Hopkins School of Medicine and co-lead of The BrainHealth Project at the Center for BrainHealth at The University of Texas at Dallas. 

 is senior scientific and technical manager at the US Army Engineer Research and Development Center, where he manages crisis response and resilience project portfolio. 

 is the CEO and president of Cohen Veterans Bioscience. 

 is cofounder of the PRODEO Institute and co-lead of the OECD NIPI, and he holds adjunct roles with IMPACT at Deakin University, GBHI at UCSF, Brain Health Nexus at Cohen Veterans Bioscience, and Baylor College of Medicine. He is a probono strategic advisor to the HEKA Fund (a collaboration of Newfund Capital and FondaMental Fondation).

The Rise of Venture Capital Investing in Mental Health

. July 29, 2021. Accessed October 12, 2021.

. August 23, 2021. Accessed October 12, 2021.

The best neuroscience news stories from January 2021

Boosting brain health after COVID-19: a convergence solution

. May 14, 2021. Accessed October 12, 2021.

Could COVID-19 finally destigmatize mental illness?

. May 13, 2020. Accessed October 12, 2021.

8. Eyre HA, Ayadi R, Ellsworth W, et al. 

A brain capital grand strategy: toward economic reimagination

Responsible innovation in technology for mental health care

Lancet Commission: inaction on mental health crisis will cost world $16 trillion by 2030

. March 25, 2021. Accessed October 12, 2021.

Gartner: 3 themes to watch in emerging technologies

. August 24, 2021. Accessed October 12, 2021.

Soaring mental health unicorns race to meet employer needs

. February 16, 2021. Accessed October 12, 2021.

How private markets embraced valuation disclosure

. April 30, 2021. Accessed October 12, 2021.

Pear Therapeutics plans to go public in $1.6B SPAC deal

. June 22, 2021. Accessed October 12, 2021.

The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality

Smartphones could be used to detect depression, Verily finds

. October 3, 2021. Accessed October 12, 2021.

21. Gastaldon C, Raschi E, Kane JM, et al. 

Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System

22. Vargas MV, Meyer R, Avanes AA, et al. 

Psychedelics and other psychoplastogens for treating mental illness

. October 4, 2021. Accessed October 12, 2021.

Investors are tripping on psychedelics startups despite a murky path to commercial success

. August 16, 2021. Accessed October 12, 2021.

. March 3, 2021. Accessed October 12, 2021.

The danger of venture capital ‘foie gras.’

. March 29, 2021. Accessed October 12, 2021.

Neurotherapeutics in the Era of Translational Medicine

Pioneering the venture studio business model

28. Fisher NF. What factors influence success in public-private partnerships? Lessons for neuroscience policy. 

What evolution can teach us about innovation

Brain health executives: a transdisciplinary workforce innovation—a commentary

. June 1, 2021. Accessed October 8, 2021.

31. Mohr DC, Azocar F, Bertagnolli A, et al. 

Banbury Forum consensus statement on the path forward for digital mental health treatment

Buyer beware: why investors and mental health practitioners must sit on the same side of the table

. May 18, 2021. Accessed October 8, 2021.

Concept to Commercialization: The Best Universities for Technology Transfer

Why companies and universities should forge long-term collaborations

. January 24, 2018. Accessed October 8, 2021.

WHO report highlights global shortfall in investment in mental health

. News release. World Health Organization. October 8, 2021. Accessed October 12, 2021.

Modern capitalism must prioritize our minds and brains

. July 22, 2021. Accessed October 12, 2021.

37. Sustainability Accounting Standards Board. 

Human capital: preliminary framework: executive summary

. Sustainability Accounting Standards Board. December 2020. Accessed September 18, 2021.

Mental health in the workplace: the world’s first International Standard just published

. June 8, 2021. Accessed September 18, 2021.

Statement on the Purpose of a Corporation

. Business Roundtable. February 2021. Accessed September 18, 2021.

COVID-19 accelerates ESG trends, global investors confirm

. September 3, 2020. Accessed September 18, 2021.

41. Linkov I, Moberg E, Trump BD, et al. 

Multi-Criteria Decision Analysis: Case Studies in Engineering and the Environment

42. Smith E, Heinemeyer M, Wolfe J, et al. 

Sustaining investment in brain health: the dangers of information asymmetry

. October 12, 2021. Accessed October 12, 2021.

“Black box” pharmacogenetic decision-support tools in psychiatry

Hype cycle of the top 50 emerging digital health trends by The Medical Futurist

. October 5, 2021. Accessed October 12, 2021.

Articles

New approaches to ensure that the brain health technology sector continues to flourish for decades.

Avoiding a Brain Health Innovation Market Failure: Lessons from the Hype Cycle

Banning Alcohol, but Not the Unvaccinated, on Airplanes

I have just taken a flight on Spirit Airlines, which continues to allow the drinking of spirits. Southwest and American Airlines, however, both continue to ban alcohol, with the reasoning that alcohol has contributed to increased disruptive behavior of passengers.

On the other hand, unvaccinated passengers are still allowed to fly, which also means that they are in airports with fellow passengers for long periods of time. I found that the shuttle buses to rental cars were jam packed. In contrast, when I went to an outdoor music festival, proof of vaccination was required.

Psychiatric Views on the Daily News is a series with a new installation every Monday, Tuesday, Thursday, and Friday. If you're interested in reading more, see the 

Doesn’t it seem that the unvaccinated should also be banned on airlines and in airports for health and mental health reasons, and that health care professionals should support such a mandate? How else are we now going to end the pandemic without mandates where possible? Or, is this another case of profits taking priority over health, as it does in so many of our health insurance systems?

We Need to Care About the Mental Health of Police, Too

On Monday, September 13, 2021, loved ones and colleagues gathered to share memories of former Milwaukee police officer Tom Kline, who took his own life a year ago. National data indicate that more law enforcement officers have died by suicide than in the line of duty over the past 5 years. Police have very high burn out rates, approaching the epidemic rate experienced by physicians.

The root reasons for the suicides are many. Some are similar to those suffered by mental health caregivers. Burnout is one; family problems are another. There may be guilt, perhaps unconscious at times, from the public charge of racism. There is the trauma.

As one former police officer said, “I can still picture every baby that has passed away or has been killed. When I’m sleeping, I can picture them in my dreams. That’s an image I’m never going to forget.”

Perhaps he could forget them with beneficial treatment. But treatment has been hard to get, and there is often a reluctance to admit that it is needed.

Posttraumatic stress disorder in police is especially challenging because it often does not qualify them for workers’ compensation. Thankfully, on October 1 a bill in my home state of Wisconsin went into effect to provide just that. Besides the financial compensation, the bill will make it easier to get needed psychiatric treatment. These and other related developments for police well-being are long overdue.

Minor League Baseball Players With Major Mental Health Problems

On September 30, ESPN published an article titled: “Can a Union Fix This? Minor Leaguers Say Poverty-Level Pay, Poor Housing Are Driving a Mental Health Crisis.”

The article began with the description of a failed suicide attempt of a minor league baseball player, Kieran Lovegrove, who had financial and other problems. He then felt that he was meant to speak out about mental health in the minor leagues. Most players are reluctant to jeopardize their careers by doing so.

In the midst of starting the highly profitable Major League Baseball (MLB) playoffs and World Series, whose players often have multimillion-dollar, multiyear contracts, we have the minor leagues—the feeding grounds to MLB—suffering from financial and mental health crises. It sort of parallels the more general great and growing divide in our country between the rich and poor. Moreover, although psychiatric and psychological care has infused MLB, it has not been readily available for the minor leaguers. Fortunately, the works and actions of Lovegrove and other minor leaguers seem to be getting the attention of MLB owners. May this also get the attention of the rest of society as another underserved group in mental health care.

Professional baseball has legal protection against the use of unions. So do businesses involved in health care, such that psychiatrists and other physicians cannot unionize. Without that, the courage of speaking out against mental harm takes on added weight and necessity wherever it is in such systems, the latest being about Facebook. The desired outcome, of course, is better mental health in those systems and their users.

One of the well-known Biblical stories is that of brothers Cain and Abel, who were said to be the children of the first parents, Adam and Eve. Cain killed Abel, and when confronted by God, he responded, “Am I my brother’s keeper?”

The media recently reported that Jeffrey Burnham also was not his brother’s keeper. On September 29, he allegedly killed his pharmacist brother and 2 others because his brother was “killing people with the COVID shot.”

Leading up to this tragedy, the news reported him worrying his mother about his possible intentions. She apparently called the local police more than once with concerns about her son’s mental stability. At some point, the police sent out an alert, but Burnham was not seen until he was arrested the day after the killings, when he confessed his guilt.

Besides the unknown individual and family history of Burnham and his brother, several social psychiatric issues and questions come readily to the fore:

1. Was Burnham influenced by any of the hundreds of websites reporting misinformation about COVID-19?

2. Given that mental illness is associated with increased violence only if it is severe and untreated, was that the case here?

3. Did the police unit in this case have mental health professionals embedded in their system to help assess the original concerns of the mother and perhaps prevent this outcome?

4. More generally, are we failing as a society and sometimes as a family to be our brothers’ and sisters’ keepers?

On October 1, the Guardian predicted there could be thousands of labor strikes within weeks in the US. About 10,000 John Deere workers just went on strike.

 About 60,000 Hollywood entertainment workers were planning to strike if their working conditions did not improve. Almost 100% of Kaiser Permanente’s nurses and health care workers authorized a strike vote, although physicians were not part of that process. Nevertheless, more physicians are now employed in such health care organizations than in private practice.

At the same time, we know that burnout has been escalating over recent years. For physicians, the rate is at epidemic proportions and escalating even more since the pandemic, but it is also climbing in other professions and in parents.

Physicians have traditionally not gone on strike in the US. Although legal reasons are sometimes posed as the big obstacle, psychological restraints may be the hardest to overcome. These include feeling that we are professionals, not workers or laborers. We tend to feel—and are taught—that we are strong and tough, and therefore can overcome any obstacle. Also, our primary ethical principle is to put patients first, even though we all know that in a crisis on an airplane, we need to put our own oxygen mask on first in order to best help others. Perhaps now is the time for psychiatrists to reconsider joining others in striking.

1. Lee J. Can a union fix this? Minor leaguers say poverty-level pay, poor housing are driving a mental health crisis. ESPN. September 30, 2021. Accessed October 5, 2021. 

https://www.espn.com/mlb/story/_/id/32172108/can-union-fix-minor-leaguers-say-poverty-level-pay-poor-housing-driving-mental-health-crisis

2. Sainato M. Wave of US labor unrest could see tens of thousands on strike within weeks. The Guardian. October 1, 2021. Accessed October 15, 2021. 

https://www.theguardian.com/us-news/2021/oct/01/us-labor-unrest-unions-strikes

Take a look at this collection of articles from H. Steven Moffic, MD's series. 

Psychiatric Views on the Daily News 

is a neurodevelopmental pediatrician currently practicing in at Pediatric Neurology, PA and Epilepsy Research Center Winter Park, Florida. He recently transitioned to a new practice, before that time, Lopez was the director of the Children’s Developmental Center. He specializes in ADHD and neurodevelopmental disorders and has participated in research on ADHD in children and adolescents, as well as the efficacy and safety of medications for generalized anxiety disorder, major depressive disorder, obsessive compulsive disorder.

Frank Lopez, MD, talks important topics to remember when treating attention-deficit/hyperactivity disorder (ADHD). 

Recent research indicates 6.1 million children, or 3 per classroom, possess the symptoms for an attention-deficit/hyperactivity disorder diagnosis. 

ADHD: 3 Kids Per Classroom

My wife and I do not watch much TV, but we almost always watch CBS Sunday Morning. I am not sure that the show this past Sunday, which had 2 segments on posttraumatic stress disorder (PTSD) and veterans, was a follow-up to the just passed Veterans Day, but it sure seemed that way.

This show’s cover story was on “New hope in treating PTSD with psychedelic drugs.”

 It focused on a veteran of 2 tours in Iraq, who had been struggling with severe PTSD for about a dozen years. Treatment as usual was not helping, as is often the case with PTSD, especially when there is moral injury involved. In his case, he felt strong guilt about being unable to rescue, but only being able to watch, another fellow soldier burn to death from an explosive device.

He then heard of a US Food and Drug Administration therapeutic breakthrough trial on psychedelics for treating PTSD and was able to enroll. The treatment was MDMA, aka ecstasy, with the crucial complement of psychotherapy. After 3 sessions, his symptoms dissipated and have continued to do so.

Later in the show, there was a report about a woman who had found 2 Army uniforms in a dumpster. Finding that unusual, she wanted to find the owner, but only had the last name of McKenzie on a jacket. Eventually, she found out they were from a veteran who had served twice in Afghanistan, developed PTSD, and then died from suicide in 2018. She decided to make the 1000 mile drive to his wife and teenage son to deliver them in person. The son was overwhelmed and felt that she returned more than the uniforms. She returned hope for the future. If only the father could have tried a psychedelic.

Hopefully, the outstanding results and protocols will continue to pan out in this new paradigm.

1. CBS Sunday Morning. New hope in treating PTSD with psychedelic drugs. YouTube. November 14, 2021. Accessed November 16, 2021. 

https://www.youtube.com/watch?v=rMBRgBFp7TI

Psychedelics: returning hope to veterans with PTSD. 

The Effect of Mindfulness on Outcomes in Psychiatric Patients

Heal Thyself, Then Heal Others? The Power of Lived Experiences

Tonsure

Mirrors and Jeweled Nets

A Deaf Football Team Sees a Way to Victory!

What About Love of the Earth

Avoiding a Brain Health Innovation Market Failure: Lessons from the Hype Cycle

Psychiatric Views on the Daily News

ADHD: 3 Kids Per Classroom

Psychedelics Providing Hope for Veterans and Others